We report the use of combination chemotherapy of gemcitabine (800 mg/m² on day1 and 8) and nedaplatin (60 mg/m² on day 1), including neoadjuvant therapy in four cases of squamous cell carcinoma of the urinary tract. In each case, the dose was reduced after assessing the performance status and renal function of the patient. Among the four cases, the best overall outcome was complete response in one case, partial response in two cases, and stable disease in one case. The main adverse event observed was thrombocytopenia; however, no serious adverse events were observed, and this regimen was safely administered. Therefore, we believe that this regimen could be an effective treatment option for progressive squamous cell carcinoma originating from the urinary tract.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.14989/ActaUrolJap_68_6_191 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of different pain management strategies during the perioperative period of esophageal squamous cell carcinoma: a retrospective cohort study.
Perioper Med (Lond)
January 2025
Department of Thoracic Surgery, The Affiliated Huaian No. 1, People's Hospital of Nanjing Medical University, Huaian, 223300, China.
Objective: This retrospective cohort study aims to evaluate and compare different postoperative pain management strategies for esophageal squamous cell carcinoma (ESCC), in order to provide scientific evidence for clinical practice and decision-making.
Methods: A total of 274 ESCC patients who underwent surgery at the Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University were included in the study.
Protective Effect of Acteoside against Hydrogen Peroxide-Induced Oxidative Damage in Human Corneal Epithelial Cells.
Bull Exp Biol Med
January 2025
Hunan University of Chinese Medicine, Changsha, Hunan, China.
We studied the effect of acteoside on a model of human corneal epithelial cells (HCEC) injury induced by HO. HCEC were divided into 4 groups and cultured for 24 h in normal medium (intact and control groups, respectively), or in a medium containing DMSO or 160 μM acteoside (DMSO and acteoside groups, respectively). Then, HO solution was added to HCEC for 4 h, except for intact cells.
View Article and Find Full Text PDFMediating role of blood metabolites in the relationship between immune cell traits and sepsis: a Mendelian randomization and mediation analysis.
Inflamm Res
January 2025
Department of Emergency Medicine, Institute of Disaster Medicine and Institute of Emergency Medicine, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, 610041, People's Republic of China.
Background: A significant association between immune cells and sepsis has been suggested by observational studies. However, the precise biological mechanisms underlying this association remain unclear. Therefore, we employed a Mendelian randomization (MR) approach to investigate the causal relationship between immune cells and genetic susceptibility to sepsis, and to explore the potential mediating role of blood metabolites.
View Article and Find Full Text PDFMetabolic rewiring in skin epidermis drives tolerance to oncogenic mutations.
Nat Cell Biol
January 2025
Department of Genetics, Yale School of Medicine, New Haven, CT, USA.
Skin epithelial stem cells correct aberrancies induced by oncogenic mutations. Oncogenes invoke different strategies of epithelial tolerance; while wild-type cells outcompete β-catenin-gain-of-function (βcatGOF) cells, Hras cells outcompete wild-type cells. Here we ask how metabolic states change as wild-type stem cells interface with mutant cells and drive different cell-competition outcomes.
View Article and Find Full Text PDFImmunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions.
Nat Rev Clin Oncol
January 2025
Department of Thoracic/Head and Neck Medical Oncology, the University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Immune-checkpoint inhibitors (ICIs) have transformed the treatment paradigm for advanced-stage squamous non-small-cell lung cancer (LUSC), a histological subtype associated with inferior outcomes compared with lung adenocarcinoma. However, only a subset of patients derive durable clinical benefit. In the first-line setting, multiple ICI regimens are available, including anti-PD-(L)1 antibodies as monotherapy, in combination with chemotherapy, or with an anti-CTLA4 antibody with or without chemotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!